Our legacy of dividend growth continues

Our century-long record of uninterrupted dividends reflects the strength of our diversified business model. 

 

Dividend investing is a well-known strategy for adding income and stability to a portfolio. Against the backdrop of 2025's market volatility, dividend-paying stocks may now hold even more appeal for investors.

Continuing our long legacy of providing shareholders with reliable returns, Abbott announced a quarterly common dividend increase of 6.8% to 63 cents per share. This marks Abbott's 54th consecutive year of dividend growth, maintaining our spot not only on the S&P 500’s Dividend Aristocrats Index but also our place among the "Dividend Kings," an elite group of companies that have raised dividends for at least 50 years in a row.

Abbott's dividend has increased more than 70% since 2020—and 350% since the 2013 separation of our research-based pharmaceuticals business, which became AbbVie. Abbott’s next payout, expected in February, will mark the company’s 408th consecutive quarterly dividend since 1924.

Our uniquely diversified business model and our focus on life-changing technologies underpins Abbott's enduring financial strength—which enables us to reward shareholders with strong returns. At the same time, in 2025, we also made meaningful advancements in multiple key business areas, including:

With more than a century of uninterrupted quarterly dividend payments and over five decades of consistent increases, Abbott's proven ability to deliver both stability and growth positions us to continue creating long-term value for our shareholders.

Learn more about Abbott's latest quarterly dividend increase.

Important Safety Information

Tendyne™ Transcatheter Mitral Valve Systems 

Rx Only

INDICATION FOR USE

The Tendyne™ Transcatheter Mitral Valve System is indicated for the treatment of symptomatic severe mitral valve dysfunction (moderate-to-severe or severe mitral regurgitation (MR), severe mitral stenosis (MS), or moderate MR with moderate or greater MS) associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair by a multidisciplinary heart team.

CONTRAINDICATIONS

The Tendyne™ Transcatheter Mitral Valve System is contraindicated in patients with:

  • anticoagulation/antiplatelet intolerance;
  • sepsis or active endocarditis;
  • evidence of left ventricular or left atrial thrombus at risk of embolization;
  • a thin or fragile apex rendering the subject unsuitable for a transapical procedure; or
  • untreatable hypersensitivity to nickel or titanium

Patients, not deemed a candidate by the local heart team based on clinical or anatomical factors should not have the Tendyne™ Transcatheter Mitral Valve procedure.

WARNINGS

  • The valve implant procedure should only be performed where emergency mitral valve surgery can be performed.
  • All sterile supplied products are for single use only. Do not reuse, reprocess, or re-sterilize components that are provided sterile. Reuse, reprocessing, or re-sterilization of these components may compromise the structural integrity of the device and/or create a risk of contamination of the device, which could result in patient injury, illness, or death.
  • Inspect all products prior to use. Do not use the valve or any component of the System if the seal or sterile barrier is compromised or if the product has been dropped, damaged, or mishandled in any way.
  • Do not use if the ‘Use By’ date specified on the package has elapsed.
  • Do not manipulate or handle the valve with sharp or pointed objects.
  • If a valve is inserted into a patient and then retrieved, it may not be reused. Do not attempt to reload it on the same or any other Delivery System.
  • Failure to properly clean and/or re-sterilize the reusable stand and reusable weight prior to use may result in infections, user injury, or patient injury (see instructions in Section 12.16).
  • The Collapsible Dilator is coated with a hydrophilic coating at the distal end of the device for a length of 8.0 centimeters. Please refer to Section 12.6 for further information on how to prepare and use this device to ensure it performs as intended. Failure to abide by the warnings in this labeling might result in damage to the device coating, which may necessitate intervention or result in serious adverse events.
  • Do not apply radial compression to the Retrieval System sheath within the 9 cm to 15 cm markings to prevent sheath damage during valve retrieval.
  • Do not use or continue to use a Retrieval System with a damaged sheath.

PRECAUTIONS

Pre-implantation Precautions

  • Long-term durability has not been established for the Tendyne™ Mitral Valve. Regular medical follow up is advised to evaluate valve performance.
  • Safety and effectiveness of the Tendyne™ Mitral Valve has not been established for the following specific populations:

            - Patients with coronary artery disease requiring intervention
            - Patients with severe tricuspid regurgitation
            - Patients with tricuspid valve disease requiring surgery
            - Patients with severe right ventricular dysfunction
            - Patients with hypertrophic or restrictive cardiomyopathy
            - Patients who are pregnant or breastfeeding
            - Pediatric patients (less than 18 years of age)

  • Pre-procedural planning, including transesophageal echocardiography and contrast-enhanced cardiac CT, should be performed to evaluate anatomic compatibility with the Tendyne prosthesis.
  • Do not use the valve if there is any damage to the container (e.g., cracked jar or lid, leakage, broken or missing seals). Do not use the valve if the container is leaking or if the glutaraldehyde storage solution does not completely cover the valve.
  • Do not freeze or expose to extreme heat. Check the temperature indicator prior to use. Do not use if the temperature indicator identifies exposure to a high or low temperature.
  • The valve and the glutaraldehyde storage solution are sterile. The outside of the valve container is non-sterile and must not be placed in the sterile field.
  • Exposure to glutaraldehyde may cause irritation of the skin, eyes, nose, and throat. Avoid prolonged or repeated exposure to the vapors. Use only with adequate ventilation. If skin contact occurs, immediately flush the affected area with water. In the event of eye contact, flush with water and seek medical attention immediately. For more information about glutaraldehyde exposure, request a Safety Data Sheet (SDS) from Abbott.
  • Care should be exercised in patients with hypersensitivities or allergies to aldehyde, silicone, polymeric materials and/or contrast.
  • Do not use the valve without thoroughly rinsing it, as directed. Adequate rinsing of the valve with sterile heparinized saline is mandatory before implantation (see Instructions for Use in Section 12.4).
  • During rinsing, do not touch the leaflets or squeeze the valve.
  • Do not expose the valve to solutions other than the storage and rinse solutions.
  • Do not add antibiotics or any other substance (other than heparin) to either the storage or rinse solutions.
  • Do not allow the valve to dry. Maintain tissue hydration with irrigation or immersion.
  • If a valve is damaged during loading, do not use or attempt to repair it.
  • Failure to properly clean and dry the reusable stand and reusable weight may lead to a reduction in device life. Do not use ultrasonic cleaning processes, steel wool, metallic wire brushes, pipe cleaners, or abrasive detergents. Do not use saline to clean or soak the device. Do not use chlorine bleach (see Instructions for Use in Section 12.16). Implantation Precautions
  • The valve is to be used in conjunction with the Tendyne™ Delivery and Retrieval Systems only.
  • Do not introduce air into the System. Ensure that the components remain free of air by flushing with sterile saline.
  • Do not deform the valve more than what is necessary for loading and implantation.
  • Do not use Delivery System or Retrieval System components if they have been dropped, damaged, or mishandled in any way.
  • Monitor valve position and performance if making induced volume or hemodynamic changes.

POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

Adverse events potentially associated with use of the Tendyne™ Transcatheter Mitral Valve System may include, but are not limited to, the following:

  • Death
  • Adverse foreign body response
  • Adverse reaction to anesthesia
  • Allergic reaction
  • Anemia
  • Annular dissection
  • Aortic insufficiency
  • Atrial or ventricular injury
  • Atrial Septal Defect (resulting from transseptal mitral valvuloplasty, if performed)
  • Bioprosthetic valve dysfunction
  • Bleeding complications
  • Blood loss which may require transfusion
  • Cardiac arrest
  • Cardiac perforation
  • Conduction defect with or without need for pacemaker
  • Cardiac arrhythmia, atrial or ventricular
  • Damage to cardiac tissue and/or structures
  • Decreased LV function and/or cardiac output
  • Device embolism
  • Device erosion, migration or malposition
  • Device thrombosis
  • Embolism (air, blood clot, calcium, tissue, etc.)
  • Emergency surgery
  • Endocarditis
  • Esophageal irritation, stricture, or perforation
  • Fever
  • Foreign body response
  • Heart Failure, new or worsening
  • Hematoma
  • Hemolysis
  • Hypotension
  • Infection / Sepsis
  • Leaflet, chordal, papillary or ventricular rupture (resulting from mitral valvuloplasty, if performed)
  • Liver failure
  • Mitral valve injury
  • Mitral valve prolapse / stenosis
  • Myocardial infarction
  • Obstruction
  • Pain
  • Pleural effusion
  • Pulmonary embolism
  • Pulmonary hypertension
  • Paravalvular leak
  • Pericardial effusion / tamponade
  • Renal insufficiency or failure
  • Respiratory difficulty, insufficiency or failure
  • Stroke or transient ischemic attack
  • Tear or damage to device
  • Vascular and access-related complications
  • Worsening of mitral regurgitation
Loading...